来自官方财务报表的收入、利润与现金流历史。
诺华公司在瑞士和国际上研究、开发、制造、分销、营销和销售药品。该公司提供 Entresto，一种血管紧张素受体脑啡肽酶抑制剂，用于治疗射血分数降低（HFrEF）的症状性慢性心力衰竭； Cosentyx 用于治疗斑块型银屑病、银屑病关节炎、强直性脊柱炎和非放射学中轴型脊柱关节炎； Kisqali，一种选择性口服细胞周期蛋白依赖性激酶 4 和 6 (CDK4/6) 抑制剂； Promacta/Revolade 用于治疗免疫性血小板减少症（ITP）、血小板减少症和严重再生障碍性贫血（SAA）患者； Tafinlar+Mekinist，一种口服联合疗法，用于治疗某些类型的癌症患者； Jakavi 用于治疗骨髓纤维化、真性红细胞增多症和急性或慢性移植物抗宿主病（GvHD）。它还提供Tasigna用于治疗费城染色体阳性慢性粒细胞白血病的慢性和/或加速期； Xolair用于治疗过敏性哮喘合并鼻息肉或严重慢性鼻鼻炎合并鼻息肉； Ilaris 可治疗发烧综合症、斯蒂尔氏病和急性痛风性关节炎； Pluvicto 治疗前列腺特异性膜抗原阳性转移性去势抵抗性前列腺癌；善宁SC和善宁LAR用于治疗肢端肥大症类癌和其他类型的功能性胃肠道和胰腺神经内分泌肿瘤； Zolgensma 用于治疗脊髓性肌萎缩症的遗传根源；卢森蒂斯； Leqvio 降低低密度脂蛋白胆固醇；卢塔瑟拉；塞姆布利克斯；和法布哈尔塔。
机器翻译
| 利润表 | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 总收入 | $56.2B | $54.8B | $51.7B | $46.7B | $43.5B | $44.0B | $49.9B | $48.7B | $46.1B | $43.4B | $49.4B | $50.4B | $53.6B | $52.7B | $52.0B | $59.4B | $51.6B | $45.1B | $42.6B | $38.9B | $35.1B |
| 毛利 | $41.9B | $41.1B | $38.9B | $34.2B | $31.9B | $32.2B | $34.8B | $34.3B | $31.6B | $29.8B | $31.9B | $33.0B | $36.3B | $36.1B | $36.1B | $40.4B | $37.1B | $32.9B | $31.1B | $27.9B | $25.7B |
| 毛利率% | 74.6% | 75.0% | 75.2% | 73.3% | 73.4% | 73.3% | 69.7% | 70.4% | 68.5% | 68.6% | 64.6% | 65.5% | 67.7% | 68.5% | 69.5% | 68.0% | 71.9% | 73.0% | 73.1% | 71.7% | 73.2% |
| 营业利润（EBIT） | $17.0B | $17.1B | $14.5B | $9.8B | $7.9B | $10.1B | $10.2B | $9.1B | $8.4B | $8.7B | $8.3B | $9.0B | $11.1B | $11.0B | $11.5B | $10.8B | $11.5B | $10.0B | $9.0B | $6.8B | $7.6B |
| 营业利润率% | 30.3% | 31.1% | 28.1% | 20.9% | 18.3% | 22.9% | 20.3% | 18.7% | 18.2% | 20.1% | 16.7% | 17.8% | 20.7% | 20.8% | 22.1% | 18.2% | 22.4% | 22.1% | 21.1% | 17.4% | 21.8% |
| 净利 | $12.8B | $14.1B | $11.9B | $14.8B | $7.0B | $24.0B | $8.1B | $11.7B | $12.6B | $7.7B | $6.7B | $17.8B | $10.2B | $9.2B | $9.3B | $8.9B | $9.8B | $8.4B | $8.2B | $11.9B | $7.2B |
| 净利润率 % | 22.7% | 25.6% | 23.1% | 31.8% | 16.0% | 54.6% | 16.2% | 24.1% | 27.4% | 17.8% | 13.6% | 35.3% | 19.0% | 17.4% | 17.8% | 15.1% | 19.0% | 18.6% | 19.2% | 30.7% | 20.4% |
| EBITDA | — | $23.0B | $20.7B | $18.3B | $14.7B | $30.9B | $17.2B | $15.6B | $20.2B | $14.6B | $14.6B | $14.3B | $17.7B | $15.9B | $16.4B | $17.1B | $15.8B | $12.8B | $12.5B | $10.6B | $10.2B |
| 每股收益（EPS） | $6.63 | $7.19 | $5.87 | $7.10 | $3.17 | $10.63 | $3.52 | $5.06 | $5.38 | $3.25 | $2.80 | $7.29 | $4.13 | $3.70 | $3.79 | $3.70 | $4.26 | $3.69 | $3.59 | $5.13 | $3.04 |
| 已发行股数 (M) | — | 1,955M | 2,035M | 2,092M | 2,197M | 2,260M | 2,296M | 2,319M | 2,344M | 2,371M | 2,400M | 2,438M | 2,470M | 2,479M | 2,445M | 2,413M | 2,301M | 2,277M | 2,284M | 2,329M | 2,360M |
来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。
资产负债表、现金流、季度数据与完整财务比率见 NVS 交互式查看器。 /companies/us/NVS
本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。
About TickerBase · Data methodology & sources · Privacy · Terms